Merck Reports Positive HYPERION Results for Pulmonary Hypertension Therapy
RAHWAY, N.J., Sept. 30, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
rare diseases
Advertisement
Sanofi Expands Sanofi Ventures With $625M to Drive Biotech Innovation
PARIS, Sept. 24, 2025 — Sanofi announced a $625 million capital expansion for its corporate venture fund, Sanofi Ventures,...
EU Approves ROMVIMZA™, First Therapy for TGCT Patients in Europe
Brussels, Belgium – September 17, 2025 – In a landmark development for rare disease patients, the European Commission (EC)...
AMO Pharma Reports Long-Term Safety Data of AMO-02 in DM1
LONDON, Sept. 15, 2025 – AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company dedicated to rare genetic...
REGENXBIO Reports Positive 12-Month Data from RGX-121 CAMPSIITE® Trial in MPS II
EGENXBIO Inc. (Nasdaq: RGNX) announced positive 12-month pivotal data from its Phase I/II/III CAMPSIITE® trial of RGX-121 (clemidsogene lanparvovec),...
Advertisements
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...
Andelyn Biosciences Partners with Tern Therapeutics for Late-Stage Manufacturing of AAV Gene Therapy for CLN2 Batten Disease
Andelyn Biosciences, a leading cell and gene therapy CDMO, has partnered with Tern Therapeutics to perform late-stage Process Performance...
FDA Approves Updated 2025–2026 COVID-19 Vaccines from Pfizer, Moderna, and Novavax
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
FDA Ends Broad Emergency Authorization, Approves Updated COVID-19 Vaccines
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
AbbVie Acquires Gilgamesh Pharmaceuticals’ Bretisilocin, A Novel Psychedelic Therapy for Major Depressive Disorder
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation...
Advertisement
